Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 15/20 | 0.64 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | GRM5 | P41594 | 1/20 | 0.54 |
| ▸ | PPIF | P30405 | 1/20 | 0.53 |
| ▸ | GCK | P35557 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10424550 | 0.86 | PPIA (0.74) | PPIAPPIF | |
| SCHEMBL9125099 | 0.83 | PPIA (0.72) | PPIAPPIF | |
| SCHEMBL2783284 | 0.81 | PPIA (0.58) | PPIALTA4HMAPK14PPIF | |
| SCHEMBL2338840 | 0.81 | PPIA (0.61) | PPIAPPIF | |
| SCHEMBL2655744 | 0.80 | LTA4H (0.63) | PPIALTA4HMAPK14GRM5PPIF | |
| SCHEMBL23631384 | 0.79 | PPIA (0.66) | PPIALTA4HMAPK14GRM5GCK | |
| SCHEMBL18586598 | 0.79 | BRD4 (0.63) | PPIAMAPTL3MBTL1 | |
| SCHEMBL9128285 | 0.79 | PPIA (0.62) | PPIAGRM5PPIF | |
| SCHEMBL2334248 | 0.79 | GCK (0.56) | PPIAGCK | |
| SCHEMBL9126145 | 0.78 | PPIA (0.75) | PPIAPPIFMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933077-B2 | Glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2015-01-13 | — | — | US | disclosed |
| EP-1948652-B1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20100056530-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2010-03-04 | — | — | US | disclosed |
| EP-1948652-A1 | GLUCOKINASE ACTIVATORS | Array Biopharma, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007053345-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056530-A1 | GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | PPIA 3953/4885LTA4H 2696/4885MAPK14 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.